Vericel VCEL Biopsy kits — Product sales, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vericel in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Vericel’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vericel's biopsy kits — product sales, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vericel's biopsy kits — product sales, net?
- Vericel (VCEL) reported biopsy kits — product sales, net of $606K in Q1 2026.
- How has Vericel's biopsy kits — product sales, net changed year-over-year?
- Vericel's biopsy kits — product sales, net increased by 1.7% year-over-year, from $596K to $606K.
- What is the long-term trend for Vericel's biopsy kits — product sales, net?
- Over 4 years (2021 to 2025), Vericel's biopsy kits — product sales, net has grown at a 4.4% compound annual growth rate (CAGR), from $2.19M to $2.61M.
- What does biopsy kits — product sales, net mean?
- This metric represents the net revenue generated from the sale of biopsy kits used in medical procedures. It reflects the commercial performance and market adoption of the company's diagnostic or procedural hardware offerings within its specialized healthcare portfolio. Tracking this revenue stream helps investors assess the demand for the company's foundational procedural tools and their contribution to overall top-line growth.